Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Elsevier Secures Publishing Rights for Premium Titles for 2023

Elsevier

Elsevier, a leading scientific publisher, and global information analytics business specializing in science and health, announced today that it will be the new publisher of six influential society journals starting in January 2023: American Journal of Clinical Nutrition The Journal of Nutrition Journal of Thrombosis and Haemostasis American Journal of Transplantation Laboratory Investigation Modern Pathology The newly acquired titles represent the following societies and add to Elsevier’s expansive global health publishing portfolio: American Society for Nutrition ( ASN ) United States and Canadian Academy of Pathology ( USCAP ) International Society on Thrombosis and Haemostasis ( ISTH ) The American Society of Transplant Surgeons ( ASTS ) American Society of Transplantation ( AST ) All are considered internationally renowned sources of knowledge and impactful study in the fields of pathology, nutrition, transplantation, haematology and peripheral vascular disease. “ It is an honor to partner with five established societies that have trusted Elsevier as the official publisher of their important journals. True to our commitment to supporting research and clinical practice, we are dedicated to placing our full range of industry-leading resources for authors, editors, reviewers and readers, in the disposal of our latest additions. With our continuous support and seamless collaboration these six valued titles can harness the benefits of a reliable global publishing partner allowing them to maximize their contribution to scientific research and clinical practice in their respective fields” said Carl Schwarz Senior Vice President, Health and Medical Sciences, at Elsevier. Elsevier will officially welcome the journals into their portfolio beginning in January 2023. They will be part of Elsevier’s title-by-title subscription model instead of a collection. Learn more about these exceptional titles or contact us for more information. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions, and funders. Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our over 2,700 digitized journals, including The Lancet and Cell; our over 43,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Contact Details Elsevier Dan DiPietro-James, Global Media Relations Director +1 773-251-8744 dan.james@elsevier.com Company Website https://www.elsevier.com/

November 14, 2022 03:00 AM Eastern Standard Time

Fine Hygienic Holding Wins License to Market FIFA World Cup Qatar 2022™ Facial Tissues and Will Be Providing Hygiene Support During the Tournament

Fine Hygienic Holding

Football's world governing body FIFA has awarded Fine Hygienic Holding (FHH) the license to design, produce, and sell limited-edition packs of facial tissues commemorating the FIFA World Cup Qatar 2022™. FHH launched the special edition packs in hypermarkets and supermarkets in Jordan, Egypt, Saudi Arabia, the UAE, Bahrain, Oman, Kuwait, Iraq, Morocco, and Sudan in mid-September 2022. FHH will also be providing sanitation support at the tournament itself, working across the 8 stadiums, training sites, and FIFA Fan Festivals to ensure the highest level of hygiene for fans, teams, and players attending FIFA World Cup Qatar 2022™. Commenting on this occasion, James Michael Lafferty, FHH CEO, said, "“We at Fine are delighted to be supporting the hygiene program at the FIFA World Cup, and ensuring we help make this the most hygienically protected sports event since the pandemic. Our Fine Guard products, with long lasting germ protection, are a perfect solution for areas such as stadiums where constant foot traffic renders only brief disinfection with traditional products. Spectators and everyone involved can rest easy knowing FIFA is using state of the art products and technologies." The FIFA World Cup Qatar 2022™ will be the first World Cup ever to be held in the Arab World. It is scheduled to take place from November 20 to December 18, 2022, in Qatar, with matches being played across eight stadiums, hosting 32 teams. About Fine Hygienic Holding: Fine Hygienic Holding (FHH), one of the world's leading wellness groups and MENA's leading manufacturer of hygienic products, serves consumers in more than 80 countries around the world. Originally established as a paper manufacturer, FHH has transformed into a wellness company dedicated to enhancing global health and wellbeing. FHH offers a diverse array of award-winning products including sterilized facial tissues, napkins, kitchen towels, toilet paper, baby diapers, adult briefs, jumbo rolls, as well as away-from-home products to accommodate all types of private and public institutions, in addition to its advanced range of personal protective equipment (PPE) and long-lasting germ protection solutions, it also brings innovative nutritional supplements, Motiva, to the market. Contact Details FINE HYGIENIC HOLDING Rana Kawalit | │ Corporate Communication & PR Director +971 54 531 5575 Rkawalit@finehh.com Company Website https://www.finehh.com/

November 14, 2022 12:30 AM Eastern Standard Time

The Blood Supply Shortage: Why it’s Happening and How You Can Help

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/8kShJVgN2pc This is the worst blood shortage in over a decade, posing a concerning risk to patient care. Amid this crisis, doctors have been forced to make difficult decisions about who receives blood transfusions and who will need to wait until more products become available. Blood and platelet donations are critically needed to help prevent further delays in vital medical treatments. The blood supply took a major hit about as the Covid-19 pandemic took over the healthcare system. Shortages could potentially lead to the postponement of surgeries, other medical procedures, and be a major issue if a mass casualty event were to happen. Every year 4.5 million Americans will need a blood transfusion. Someone in your audience or their loved one could be in need. With the blood shortage being a major health issue potentially affecting so many, what can be done and what should we know? Dr. Glenn Ramsey, chair of the College of American Pathologists Transfusion Committee recently conducted a nationwide media tour to inform the public on what is being done. Topics that Dr. Ramsey discussed included: With the current blood shortage, the recent changes in blood donation restrictions The importance of donating blood Keeping the blood supply strong Why there is always a shortage How the current blood supply is being maximized What the most common incidents are in which blood donation is needed For more information please visit americasblood.org and newsroom.cap.org Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 11, 2022 11:00 AM Eastern Standard Time

Video

Fall Health Checklist from the College of American Pathologists

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/DotHvhg8XQw Summer is coming to a close, which means it’s the perfect time to take stock of your health and set yourself up for success the rest of the year. The FDA has recently changed their guidelines regarding Covid at-home tests, now advising people to take three tests, instead of the previously recommended two tests. The agency issued the update just ahead of the back-to-school season – an attempt to reduce the risk of infection being missed and to help people from unknowingly spreading the virus. But COVID isn’t the only thing on people’s minds. With fall approaching, cold and flu season isn’t far behind. This time of year can create confusion for people who may not be able to tell the difference between COVID symptoms and cold/flu symptoms. There are also concerns about the spread of Monkeypox and the re-emergence of Polio. During a nationwide media tour on September 15 th, Dr. Emily Volk – President of the College of American Pathologists discussed: Changing FDA guidelines around COVID testing and what you need to know Navigating flu shots and COVID boosters Tips for knowing the difference between COVID symptoms and cold/flu symptoms Additional insights on recent health concerns such as Monkeypox and Polio For more information, visit CDC.GOV or FDA.GOV Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 11, 2022 10:31 AM Eastern Standard Time

Video

Hear the Holidays: Ways to Help People with Hearing Loss Enjoy the Holidays

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/yQwa2WRw59E The holidays are a time to share special moments with loved ones and celebrate those relationships, but if you have hearing loss and are struggling to hear or follow conversations, you may feel disconnected from family and friends this holiday season. Often, feelings of embarrassment or frustration can cause individuals with hearing loss to stop socializing or participating in events or activities that they used to enjoy. According to a HearingLife and Harris Poll survey, 72% of people with hearing loss wish their hearing was better to enjoy holiday and special gatherings*. HearingLife is celebrating the holiday season with the “Hear the Magic. Love Your Ears” holiday campaign accompanied by the second annual “Magic of Giving Back” program aimed to help those with hearing loss gain back the joyful sounds of the holiday season. "We understand the challenges that come with hearing loss, such as difficulty following conversations and feeling embarrassed," said Dr. Leslie Soiles, Chief Audiologist, HearingLife. "At HearingLife, we believe everyone deserves to hear their favorite sounds of the season and we want to help those in need regain their confidence and enjoy connecting with loved ones during the holiday season." For the opportunity to receive free hearing aids through the “Magic of Giving Back,” people can submit either a personal story, or a story on behalf of a loved one, explaining why they are a candidate for the gift of hearing. To learn more and share your story, visit www.HearingLife.com/Magic by November 12th About HearingLife: HearingLife is a national hearing care company and part of the Demant Group, a global leader in hearing healthcare built on a heritage of care, health, and innovation since 1904. HearingLife operates nearly 700 hearing care centers across 42 states. We follow a scientific, results-oriented approach to hearing healthcare that is provided by highly skilled and caring professionals. Our vision is to help more people hear better through life-changing hearing health delivered by the best personalized care. To learn more, visit: https://www.hearinglife.com. *Survey Method: This survey was conducted online within the United States by The Harris Poll on behalf of HearingLife from August 19-23, 2021, among 2,044 adults ages 18+, among whom 253 have hearing loss. This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated. For complete survey methodology, including weighting variables and subgroup sample sizes, please contact hearinglife@kaplow.com. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 10, 2022 04:00 PM Eastern Standard Time

Video

Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?

Organicell Regenerative Medicine, Inc.

Learn more about Organicell Regenerative Medicine, Inc.from this latest report. During the peak of the deadly COVID-19 pandemic, one novel therapeutic that seems to have played an important role in helping save lives was Organicell Regenerative Medicine Inc. ’s (OTCMKTS: OCEL) Zofin™. Even though COVID-19 therapies and vaccines have been dominated by big players like BioNTech SE — ADR (NASDAQ: BNTX), Johnson & Johnson (NYSE: JNJ), Moderna Inc. (NASDAQ: MRNA) and Pfizer Inc. (NYSE: PFE), the U.S. Food and Drug Administration (FDA) approved Zofin™ to be used for patients — some whose conditions were serious and life-threatening. The company hit a significant milestone in October 2020 when the FDA granted expanded access for patients to be treated with their flagship therapeutic, Zofin™. The FDA gave Emergency Investigational New Drug (eIND) approval for treating COVID-19. The investigational product was used for patients with mild to moderate COVID-19 or who were judged to be at high risk of progression to moderate disease. Zofin™, manufactured to retain naturally occurring microRNAs without adding any other substance or diluent, was reportedly among the first reported acellular therapies accessed under the FDA’s approved expanded access program. The FDA approval followed the treatment of six outpatients treated under investigational new drugs (INDs) status with Zofin™. Organicell reported chalking up another win when in May 2021, the Drug Regulatory Authority of Pakistan approved Zofin™ for use with patients on compassionate grounds following the patient’s COVID-19 diagnosis and admittance to an intensive care unit for treatment on a ventilator. These huge stamps of approvals from major regulatory authorities seem to have put the spotlight on Organicell, indicating that it could be doing something extraordinary and is a company to watch. The devastating impact of the COVID-19 pandemic on humanity and the global economy has triggered a sudden wake-up call for an all-hands-on-deck approach to developing vaccines and therapies to shore up humanity’s immunity against present and future viruses. Companies like Organicell could play a key role. For most investors, identifying publicly-traded companies like Organicell with the most promising prospects for converting research and development initiatives into commercial remedies could pay off. What Makes Organicell Different? Based in Nova Southeastern University’s (NSU) Center for Collaborative Research, Organicell is a clinical-stage research company with a mission to be the first company to prove the efficacy of extracellular vesicles (EVs) — also known as exosomes — in clinical trials for several conditions. The fully integrated clinical-stage biotechnology company says it is committed to researching, developing and manufacturing new biologic medicine, focusing on current and potential regenerative therapeutics. Comprised of two arms — clinical research and commercial — Organicell generates revenue by extracting and delivering potent formulas of EVs for topical, skincare applications. The company reports that its proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, growth factors, and key proteins without adding or combining any other substance or diluent. Zofin™ Organicell is actively investigating the therapeutic safety and efficacy of Zofin™ in subjects with various stages of COVID-19 infection — mild to moderate, moderate to severe, and post-COVID-19 complications a.k.a Long Haulers. Through the FDA’s single-patient emergency and compassionate use mechanism, Organicell has treated 18 subjects to observe Zofin™ safety while secondarily observing clinical improvements. Zofin™ was administered intravenously to these patients, who were followed for 28 days post-therapy. Under expanded access, Zofin™ has been administered to patients with mild to moderate COVID-19 infections. These studies demonstrate the first use of a human perinatal-derived nanoparticle biologic as a safe and potentially efficacious treatment for acute respiratory distress syndrome induced by COVID-19 infection. Cheaper And Easier Clinical Trials? According to Organicell, Zofin™ is naturally derived and, therefore, only requires 30 patients to complete Phase I/II trials of clinical trials. Phase III trials should require only 250-300 patients, while clinical trials are currently enrolling and anticipated to be completed within 24 months. Clinical trials are a crucial element of the drug development process, but they are often expensive, with costs running into hundreds of millions of dollars. Organicell says its trials are cheaper and faster than those of other companies. The company reports that the cost per trial is approximately $10 million with only 250-350 patients needed, compared to others that cost hundreds of millions of dollars and involve more patients. “When people hear about clinical trials, they immediately get spooked because they think hundreds of millions of dollars and tens of thousands of patients,” Organicell’s President and Acting CEO Matt Sinnreich told Benzinga. “Since we are a biologic, we have a much smaller requirement.” With an entire clinical trial costing about $10 million, Sinnreich believes the company is “well positioned to get Phase I / Phase II enrolled and has a board of directors that can help with additional funding needs.” Apart from Zofin™, Organicell is also working on PPX, Factor X, and XoTin. The company says it is looking at health and beauty partnerships, clinical trials to pursue a Biologics License Application (BLA), and evolving the science to address other specific ailments. Unlike other companies that may be spending on speculative research, Organicell says it is already generating revenue with an ultimate goal to uplist soon. Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of other related services. The Company's proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Organicell Investor Relations IR@organicell.com Company Website https://organicell.com/

November 10, 2022 02:17 PM Eastern Standard Time

Dynamic Works Institute to Launch CWDP Recertification Package at NAWDP Youth Symposium

Dynamic Works Institute

Dynamic Works Institute, a leading provider of transformative training for individuals, corporations and community-based organizations, will introduce its new Certified Workforce Development Professional (CWDP) Recertification Package at the National Association of Workforce Development Professionals (NAWDP) 2022 Youth Symposium, booth 211. The show will take place from November 14-16 at The Westin Charlotte (Charlotte, N.C.). Achieving CWDP certification demonstrates that a workforce development professional has completed the required training In order to maintain their CWDP certification, workforce development professionals must complete at least 60 hours of professional development related to one or more of the five competencies identified by NAWDP, which include: Customer Service Methodology, Diversity in Workforce Development, Labor Market Information and Intelligence, Principles of Communication, and Workforce Development Structure, Policies and Programs. The new CWDP Recertification Package from Dynamic Works Institute is specifically designed and delivered by workforce training experts to accommodate the schedules of busy professionals who wish to recertify for their CWDP certification. The Recertification Package includes a selection of live and asynchronous online course options covering all five core competencies identified by NAWDP, which customers can attend as their schedules allow. “We’re excited to introduce our new CWDP Recertification program, as it addresses an unmet need to help busy workforce development professionals receive the training they need for recertification,” said Paul Dunn, CEO of Dynamic Works Institute. “Our live and asynchronous online courses work with our customers’ busy schedules to build on their current skills and help improve job performance. In addition, they are specifically designed to meet the requirements outlined by NAWDP for CWDP recertification.” Dynamic Works Institute’s new Recertification Package can provide the full 60 hours of instruction required for CWDP recertification or supplement any remaining required hours necessary. Customers can choose from a selection of 30, 15 and 10-hour course options, with packages focused on case management, customer empowerment, working with special populations, and more. In addition, all customers are enrolled in 10 hours of free live training to support their success and build a network of peers. After finishing the course, customers receive their completed NAWDP paperwork and application form available for download and submission. To learn more about Dynamic Works Institute’s new CWDP Recertification Package, stop by booth 211 at the NADWP 2022 Youth Symposium, or visit https://dynamicinstitute.com/. About Dynamic Works Institute Dynamic Works Institute offers over 300 virtual, interactive courses, coaching and live webinars to transform the value and success individuals, corporations and community-based organizations derive from their work. The company’s convenient and relevant virtual training services, complemented with extreme customer service, develop the skills and mindsets that make work life more fulfilling. Contact Details Dynamic Works Institute Gena Leisten +1 513-238-4665 gleisten@dwfs.us O’Keeffe PR Dan O’Keeffe +1 513-221-1526 dan@okeeffepr.com Company Website https://dynamicinstitute.com

November 10, 2022 10:03 AM Eastern Standard Time

The NIH Has Given BioRestorative Therapies A Stamp Of Approval

BioRestorative Therapies, Inc.

BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes. BioRestorative’s novel drug BRTX-100, which is approved by the Food and Drug Administration (FDA) to enter Phase 2 clinical trials, targets damaged and degenerating discs. The Company is well into its trial, a 99-patient prospective, randomized, double-blinded, controlled study, the gold standard of its kind. BRTX-100 is an autologous stem cell product that uses the patient’s own stem cells, which are harvested, cultured, combined with their own autologous platelet lysate and then injected directly into the affected disc to initiate the healing and repair process. Previous human investigator-initiated studies using a similar product to BRTX-100 (but arguably less potent) have shown a reduction in pain and increase in function in excess of the stated primary endpoints in BioRestorative’s phase 2 protocol. This fascinating opportunity presents a study that is highly suggestive of the potential outcomes for which they are currently processing. In addition, the treatment is anticipated to be safer, cheaper and more effective with a single treatment. BioRestorative’s other product — ThermoStem — has highly promising results in the treatment of obesity and related diseases. Obesity affects over 40% of Americans, and BioRestorative is developing a novel stem-cell population — brown adipose tissue — that shows signs of regulating metabolic activity and reducing excess fat. BioRestorative Therapies Has Joined The Leagues Of 23andMe, Qualcomm and Naviscan In September 2021, BioRestorative was awarded a Small Business Technology Transfer (STTR) phase I grant for $256,000. The project seeks to evaluate the therapeutic effects on the company’s hypoxic cultured bone marrow derived mesenchymal stem cells (BRTX-100) after encapsulation with a PEG-peptide hydrogel. The work is being done in collaboration with Dr. Lori Setton, Chair of the Department of Biomedical Engineering at Washington University in St. Louis. SBIR is a federal program coordinated by the Small Business Administration that funds research and development. STTR is a Small Business Innovation Research (SBIR) sister program. The programs are one of the largest sources of funding for early-stage companies. Big-name companies like 23andMe Holding Co. (NASDAQ: ME), Qualcomm Inc. (NASDAQ: QCOM) and Naviscan Inc. were awarded SBIR and STTR funding, which helped them become the companies they are today. SBIR and STTR programs are highly competitive programs that foster and encourage small businesses to engage in Federal Research/Research and Development (R/R&D) with the potential for product commercialization. Through this highly competitive awards-based program, SBIR and STTR enable small businesses to explore their technological potential and provide the incentive to profit from its commercialization. SBIR and STTR are like gold mines for smaller companies. Borrowing from a bank is often difficult for new, innovative businesses because they lack collateral and revenue to help secure loans. While venture capital often fills the gap, it’s not always available and companies can lose autonomy if a venture capital firm wants to have a heavier hand in decisions. With the SBIR and STTR programs, funding is stable and predictable as it is an award, not a loan. Small businesses retain intellectual property rights. Additionally, the National Institute of Health (NIH), which oversees the programs, provides recognition, validation and visibility to early-stage companies that they might not otherwise have with either a loan from a bank or venture capital. Receiving an SBIR and STTR award can also help attract more funding because of the prestige associated with the programs. SBIR and STTR programs have supported the development of 99 drugs from 1996-2020. Of these drugs, 16% of all treatments made a “significant” advance over available medicines. Companies that receive SBIR and STTR awards are put on the map and can credibly say they were backed by the NIH. With the recent grants BioRestorative Therapies has received, the NIH has given the company a stamp of approval. To learn more about BioRestorative Therapies, visit its website. BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations ir@biorestorative.com Company Website https://www.biorestorative.com/

November 10, 2022 08:00 AM Eastern Standard Time

Airly secures new $5.5M funding round to fight air pollution and save lives

Airly

Air pollution is the most-pressing environmental health crisis of our time with approximately nine in 10 people around the world breathing unclean air. Helping to spotlight this existential threat, cleantech startup Airly is today announcing a $5.5M series A funding round as it targets cleaning the air by understanding the exact sources based on sensor data and comprehensive actionable insights. The funding round was led by firstminute capital and Pi Labs with participation from existing investors including. Sir Richard Branson Family Office, AENU, Untitled and new investors including Slack co-founder Cal Henderson, Snowflake co-founder Marcin Zukowski as well as institutional investors Semapa Next and TO Ventures. With this funding round, Airly has raised $8.8M from investors since March 2021, as it now scales to realize the potential of its complete air quality monitoring platform and supporting local governments determined to fight for clean air with an end-to-end solution. The Airly platform provides solutions for air quality monitoring to local governments, companies and local communities in over 40 countries. They use sensors to observe data and now Airly will be able to provide a complete dashboard enabling users to go one step further. They will be able to monitor the data and obtain actionable insights that will translate into effective actions to improve air quality and understand their impact on health and well-being. The dashboard will offer multiple features including a report generator, insights, impact tracker and the city ranking. Wiktor Warchałowski, CEO and co-founder of Airly commented: “With the funding round we are going deeper with our users. Monitoring with our sensors has helped bring the issue to the surface and now with our dashboard offering actionable insights and nudges, we believe this will be the catalyst that helps move measures and policies into place to repair the air we breathe.” Recently, Airly launched the largest air quality monitoring network in a European city by installing 165 sensors in Warsaw. Similarly large networks have also been launched in the UK (Birmingham and the London boroughs of Lambeth, Haringey and soon Southwark) and Indonesia (Jakarta). Airly has also strategic partnerships with the likes of JCDecaux, NHS, NILU (Norwegian Institute for Air Research) and is a key partner in the European Union’s Horizon 2020 funded DivAirCity project. Airly impact studies have proven that cities with a dense network of air quality sensors are achieving faster reduction in air pollution. Since 2019, four cities from the C40 group (a global network of cities taking urgent action to confront the climate crisis) with dense monitoring networks (Jakarta, Lisbon, London and Warsaw) have improved their overall air quality by 16% (compared to 5% improvement made by cities without dense networks). “ Trailblazers in London are showing how real-time local air quality data is the catalyst for taking action to make our urban spaces healthier and more sustainable. I expect many cities and local authorities to follow their leadership, starting with more precise and local data. Airly is at the forefront of building this data infrastructure and our fight against air pollution, and we’re very proud to continue our support by co-leading their Series A” - says Brent Hoberman, co-founder and Executive Chairman of Founders Forum and firstminute capital. More than 10 million people die each year from air pollution. Exposure to air pollution increases the risk of stroke, dementia, heart disease, lung cancer and chronic respiratory diseases, with children particularly vulnerable. Last year, the World Health Organization tightened up on safe levels of air pollutants. Airly is the first platform worldwide to include the new index in its analytical tools and free-to-use community tools (incl. mobile app and web application). Stefania Ponzo, Partner at Pi Labs, commented: “ The ways in which towns and cities contribute to our health and wellbeing will shape how we live for years to come – and air quality plays a huge part in that. We believe Airly’s solution will become an essential tool in cities around the world, helping to improve liveability standards, reduce emissions, and ultimately, getting us closer to sustainability and wellness goals. We are excited at the prospect of partnering with a team that can truly go global with its impact.” About Airly Airly offers a comprehensive SaaS solution for air quality monitoring and control. It is possible by a proprietary low-cost distributed sensor network delivering hyper-local real-time air quality data. Airly provides governments, enterprises and communities decision-ready data on air quality. Airly enables organisations to monitor air quality, analyse trends and sources, develop targeted initiatives to combat pollution, and track improvements. Thanks to that, they’re supporting organisations in their journey to eliminate pollution, improve air quality and protect public health. Airly recently won a number of landmark public tenders such as London’s Borough Lambeth, Birmingham and one of Europe’s largest contracts with the City of Warsaw. Airly can build on a significant and ever growing customer base comprising over 600 local authorities. The company also cooperates with global brands such as JC Decaux, Bolt, E-on, Philips, Skanska and Veolia. For more information visit www.airly.org Contact Details Airly Marcin Gnat +48 507 416 727 m.gnat@airly.org Company Website https://airly.org/en/

November 10, 2022 07:00 AM Eastern Standard Time

Image

1 ... 162 163 164 165 166 ... 250